Molecular characterization of the circadian clock in patients with Parkinson's disease-CLOCK4PD Study protocol.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 05 10 2023
accepted: 02 06 2024
medline: 19 7 2024
pubmed: 19 7 2024
entrez: 19 7 2024
Statut: epublish

Résumé

Circadian rhythms (CRs) orchestrate intrinsic 24-hour oscillations which synchronize an organism's physiology and behaviour with respect to daily cycles. CR disruptions have been linked to Parkinson's Disease (PD), the second most prevalent neurodegenerative disorder globally, and are associated to several PD-symptoms such as sleep disturbances. Studying molecular changes of CR offers a potential avenue for unravelling novel insights into the PD progression, symptoms, and can be further used for optimization of treatment strategies. Yet, a comprehensive characterization of the alterations at the molecular expression level for core-clock and clock-controlled genes in PD is still missing. The proposed study protocol will be used to characterize expression profiles of circadian genes obtained from saliva samples in PD patients and controls. For this purpose, 20 healthy controls and 70 PD patients will be recruited. Data from clinical assessment, questionnaires, actigraphy tracking and polysomnography will be collected and clinical evaluations will be repeated as a follow-up in one-year time. We plan to carry out sub-group analyses considering several clinical factors (e.g., biological sex, treatment dosages, or fluctuation of symptoms), and to correlate reflected changes in CR of measured genes with distinct PD phenotypes (diffuse malignant and mild/motor-predominant). Additionally, using NanoStringⓇ multiplex technology on a subset of samples, we aim to further explore potential CR alterations in hundreds of genes involved in neuropathology pathways. CLOCK4PD is a mono-centric, non-interventional observational study aiming at the molecular characterization of CR alterations in PD. We further plan to determine physiological modifications in sleep and activity patterns, and clinical factors correlating with the observed CR changes. Our study may provide valuable insights into the intricate interplay between CR and PD with a potential to be used as a predictor of circadian alterations reflecting distinct disease phenotypes, symptoms, and progression outcomes.

Identifiants

pubmed: 39028707
doi: 10.1371/journal.pone.0305712
pii: PONE-D-23-32151
doi:

Substances chimiques

CLOCK Proteins EC 2.3.1.48

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0305712

Informations de copyright

Copyright: © 2024 Yalçin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

A.R. has filled patents (PCT/EP2021/073798 and PCT/EP2021/073802) related to biomarkers for detecting the clock. M.Y., R.P., J.F., C.B., C.S. and T.G. declare no financial or non-financial competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The funders had no role in the design of the study or writing of the manuscript.

Auteurs

Müge Yalçin (M)

Institute for Theoretical Biology (ITB), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Molecular Cancer Research Center (MKFZ), Medical Department of Hematology, Oncology, and Tumour Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Institute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, Germany.

Ana Rita Peralta (AR)

EEG/Sleep Laboratory, Department Neurosciences and Mental Health, Unidade Local de Saude Santa Maria-ULSSM, Lisbon, Portugal.
Department of Neurology, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Instituto de Fisiologia, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
CNS-Campus Neurológico, Torres Vedras, Portugal.
Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Carla Bentes (C)

EEG/Sleep Laboratory, Department Neurosciences and Mental Health, Unidade Local de Saude Santa Maria-ULSSM, Lisbon, Portugal.
Department of Neurology, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Cristiana Silva (C)

CNS-Campus Neurológico, Torres Vedras, Portugal.

Tiago Guerreiro (T)

LASIGE, Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal.

Joaquim J Ferreira (JJ)

Department of Neurology, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
CNS-Campus Neurológico, Torres Vedras, Portugal.
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Angela Relógio (A)

Institute for Theoretical Biology (ITB), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Molecular Cancer Research Center (MKFZ), Medical Department of Hematology, Oncology, and Tumour Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Institute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH